

3rd HBM-PT

Workshop on Human BioMonitoring in Portugal

18 November 2020 **Online edition**



Book of abstracts















3rd HBM-PT

Workshop on Human BioMonitoring in Portugal

18 November 2020 Online edition

Organising Committee

Ana Tavares (Instituto Nacional de Saúde Doutor Ricardo Jorge) Ana Virgolino (ISAMB, Faculdade de Medicina da Universidade de Lisboa) Isabel Moura (Agência Portuguesa do Ambiente) Joana Costa (ISAMB, Faculdade de Medicina da Universidade de Lisboa) Marta Abrantes (Fundação para a Ciência e a Tecnologia) Rita Cavaleiro (Fundação para a Ciência e a Tecnologia) Susana Viegas (Escola Nacional de Saúde Pública)

Scientific Committee

Ana Virgolino (ISAMB, Faculdade de Medicina da Universidade de Lisboa) Carina Ladeira (Escola Superior de Tecnologia da Saúde de Lisboa) Carlos Dias (Instituto Nacional de Saúde Doutor Ricardo Jorge) Edna Ribeiro (Escola Superior de Tecnologia da Saúde de Lisboa) Henriqueta Louro (Instituto Nacional de Saúde Doutor Ricardo Jorge) Joana Costa (ISAMB, Faculdade de Medicina da Universidade de Lisboa) Maria João Silva (Instituto Nacional de Saúde Doutor Ricardo Jorge) Paula Alvito (Instituto Nacional de Saúde Doutor Ricardo Jorge) Ricardo Assunção (Instituto Nacional de Saúde Doutor Ricardo Jorge) Sónia Namorado (Instituto Nacional de Saúde Doutor Ricardo Jorge) Teresa Borges (Direção-Geral da Saúde)



Dietary acrylamide intake and risk of cancer: a systematic review

Carolina Capitão^{1†}, Raquel Martins^{1†}, Thorhallur I. Halldorsson^{2,3}, Tommaso Filippini⁴, Marco Vinceti^{4,5}, Osvaldo Santos^{1,6}, Ana Virgolino¹, Federica Laguzzi⁷

¹ EnviHeB Lab, Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; ² Centre for Fetal Programming, Department of Epidemiology Research, Copenhagen, Denmark; ³ Unit for Nutrition Research, Faculty of Food Science and Nutrition, University of Iceland, Reykjavík, Iceland; ⁴ Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy; ⁵ Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts; ⁶ Unbreakable Idea Research, Cadaval, Portugal; ⁷ Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

[†] These authors contributed equally

* Corresponding author: carolinacapitao@medicina.ulisboa.pt

Objectives: To explore the association between dietary acrylamide exposure and the risk of different cancers in prospective studies.

Methods: PubMed, Web of Science and Scopus databases were searched for studies published in English, until 18 June 2020. Eligible studies included adults, assessment of dietary acrylamide and cancer incidence, reported as hazard ratio (HR) for acrylamide intake as a continuous variable (per 10µg/day increase). Breast, endometrial, ovarian, and renal cell cancers were excluded. Quality of papers was assessed using the NIH's Quality Assessment Tool for Observational Cohort and Cross-sectional Studies.

Results: Out of the 855 papers identified, 10 were included, providing a dataset of 526,151 participants, of which 13,629 developed cancer. The mean follow-up period was 14.5 years. All studies were found to have fair quality. Multivariate-adjusted pooled HR showed no clear association for almost all cancer diagnosis included per 10µg/day increase of exposure. As exceptions, in men, pooled HR showed an increased association between a consumption increment of 10µg/day and the following cancers: cutaneous malignant melanoma [HR=1.13 (95%CI:1.10-1.26)], follicular lymphoma [HR=1.28 (95%CI:1.03-1.61)], and multiple myeloma [HR=1.14 (95%CI:1.01-1.27)]. In women a decreased risk of lung cancer was noted [HR=0.82 (95%CI:0.69-0.96)].

Conclusions: This systematic review suggests that dietary acrylamide exposure may increase the risk of cutaneous malignant melanoma, follicular lymphoma and multiple myeloma in men only. More studies are needed to confirm the effect of dietary acrylamide in the development of each cancer type, to improve current knowledge regarding the risks associated to the current exposure of the population to this substance.

Funding: The HBM4EU project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733032. The development of this work has also benefited from the ISAMB's base-funding from Fundação para a Ciência e a Tecnologia (Ref. UID-B/04295/2020).

KEYWORDS | acrylamide; dietary exposure; neoplasms; epidemiological studies; systematic review

NATIONAL HUB CONTACT POINT

Rita Cavaleiro rita.cavaleiro@fct.pt Tel: (351) 213 911 541

FCT - Fundação para a Ciência e a Tecnologia

Av. D. Carlos I, 126 - 7° 1249 - 074 LISBOA Portugal

The HBM4EU Initiative has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement N° 733032.